A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)

Summary

This is a phase I, open-label, dose-escalation trial of TG6050 administered by single or repeated IV infusion(s).

Timeline

Start

2023-04-05

Primary completion

2025-06-23

Completion

2025-06-23

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision not related to safety”

Publications

• Azar F, Deforges J, Demeusoit C, Kleinpeter P, Remy C, Silvestre N, Foloppe J, Fend L, Spring-Giusti C, Quemeneur E, Marchand JB. TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment. J Immunother Cancer. 2024 Jul 25;12(7):e009302. doi: 10.1136/jitc-2024-009302.

Drugs

Indications